USD 34.24
(-1.28%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 189.94 Million USD | -0.12% |
2022 | 190.17 Million USD | 270.9% |
2021 | 51.27 Million USD | 4.45% |
2020 | 49.08 Million USD | -3.26% |
2019 | 50.73 Million USD | 316.64% |
2018 | 12.17 Million USD | -16.19% |
2017 | 14.53 Million USD | -92.32% |
2016 | 189.12 Million USD | -50.42% |
2015 | 381.43 Million USD | 5.47% |
2014 | 361.65 Million USD | 4.15% |
2013 | 347.23 Million USD | 3.43% |
2012 | 335.73 Million USD | 84.96% |
2011 | 181.51 Million USD | -12.92% |
2010 | 208.45 Million USD | 161.83% |
2009 | 79.61 Million USD | -32.34% |
2008 | 117.68 Million USD | -3.16% |
2007 | 121.51 Million USD | -0.11% |
2006 | 121.65 Million USD | -18.27% |
2005 | 148.84 Million USD | 1.01% |
2004 | 147.35 Million USD | 32.65% |
2003 | 111.08 Million USD | 50.25% |
2002 | 73.93 Million USD | 51.06% |
2001 | 48.94 Million USD | 227.38% |
2000 | 14.95 Million USD | 12.41% |
1999 | 13.3 Million USD | 0.0% |
1998 | - USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q2 | 198.01 Million USD | -1.71% |
2024 Q3 | 194.44 Million USD | -1.8% |
2024 Q1 | 201.46 Million USD | 6.07% |
2023 Q3 | 190.85 Million USD | -1.97% |
2023 FY | 189.94 Million USD | -0.12% |
2023 Q1 | 186.94 Million USD | -1.69% |
2023 Q2 | 194.69 Million USD | 4.14% |
2023 Q4 | 189.94 Million USD | -0.48% |
2022 Q3 | 159.83 Million USD | -0.73% |
2022 Q2 | 161.01 Million USD | 217.99% |
2022 FY | 190.17 Million USD | 270.9% |
2022 Q1 | 50.63 Million USD | -1.24% |
2022 Q4 | 190.17 Million USD | 18.98% |
2021 Q2 | 53.22 Million USD | 0.73% |
2021 Q1 | 52.83 Million USD | 7.64% |
2021 FY | 51.27 Million USD | 4.45% |
2021 Q4 | 51.27 Million USD | -1.88% |
2021 Q3 | 52.25 Million USD | -1.82% |
2020 Q4 | 49.08 Million USD | 3.07% |
2020 Q1 | 47.88 Million USD | -5.63% |
2020 Q2 | 48.33 Million USD | 0.94% |
2020 Q3 | 47.62 Million USD | -1.46% |
2020 FY | 49.08 Million USD | -3.26% |
2019 Q1 | 19.95 Million USD | 63.89% |
2019 FY | 50.73 Million USD | 316.64% |
2019 Q4 | 50.73 Million USD | 114.04% |
2019 Q3 | 23.7 Million USD | 5.15% |
2019 Q2 | 22.54 Million USD | 12.95% |
2018 Q4 | 12.17 Million USD | -3.49% |
2018 Q1 | - USD | -100.0% |
2018 Q3 | 12.61 Million USD | -38.88% |
2018 FY | 12.17 Million USD | -16.19% |
2018 Q2 | 20.64 Million USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | 14.53 Million USD | 0.0% |
2017 Q2 | - USD | -100.0% |
2017 Q1 | 113.34 Million USD | -40.07% |
2017 FY | 14.53 Million USD | -92.32% |
2016 Q2 | 396.05 Million USD | 1.9% |
2016 Q4 | 189.12 Million USD | -0.91% |
2016 Q1 | 388.65 Million USD | 1.89% |
2016 Q3 | 190.85 Million USD | -51.81% |
2016 FY | 189.12 Million USD | -50.42% |
2015 Q1 | 368.43 Million USD | 1.87% |
2015 FY | 381.43 Million USD | 5.47% |
2015 Q4 | 381.43 Million USD | 0.94% |
2015 Q3 | 377.88 Million USD | 1.79% |
2015 Q2 | 371.22 Million USD | 0.76% |
2014 Q1 | 343.01 Million USD | -1.21% |
2014 Q3 | 355.21 Million USD | 1.79% |
2014 Q2 | 348.97 Million USD | 1.74% |
2014 FY | 361.65 Million USD | 4.15% |
2014 Q4 | 361.65 Million USD | 1.81% |
2013 Q1 | 330.85 Million USD | -1.45% |
2013 Q4 | 347.23 Million USD | 1.65% |
2013 Q3 | 341.59 Million USD | 1.62% |
2013 Q2 | 336.13 Million USD | 1.6% |
2013 FY | 347.23 Million USD | 3.43% |
2012 Q2 | 182.69 Million USD | 0.35% |
2012 Q3 | 335.29 Million USD | 83.52% |
2012 FY | 335.73 Million USD | 84.96% |
2012 Q4 | 335.73 Million USD | 0.13% |
2012 Q1 | 182.06 Million USD | 0.3% |
2011 FY | 181.51 Million USD | -12.92% |
2011 Q3 | 209.95 Million USD | -0.21% |
2011 Q4 | 181.51 Million USD | -13.55% |
2011 Q2 | 210.39 Million USD | 1.13% |
2011 Q1 | 208.02 Million USD | -0.21% |
2010 Q3 | 234.91 Million USD | -0.52% |
2010 Q1 | 76.37 Million USD | -4.08% |
2010 Q2 | 236.14 Million USD | 209.21% |
2010 Q4 | 208.45 Million USD | -11.26% |
2010 FY | 208.45 Million USD | 161.83% |
2009 Q1 | 113.75 Million USD | -3.34% |
2009 Q2 | 110.09 Million USD | -3.21% |
2009 Q3 | 106.43 Million USD | -3.32% |
2009 Q4 | 79.61 Million USD | -25.2% |
2009 FY | 79.61 Million USD | -32.34% |
2008 Q1 | 117.88 Million USD | -2.99% |
2008 FY | 117.68 Million USD | -3.16% |
2008 Q4 | 117.68 Million USD | -4.62% |
2008 Q3 | 123.37 Million USD | -3.51% |
2008 Q2 | 127.86 Million USD | 8.47% |
2007 Q1 | 119.15 Million USD | -2.05% |
2007 Q4 | 121.51 Million USD | 8.14% |
2007 Q3 | 112.36 Million USD | -2.58% |
2007 FY | 121.51 Million USD | -0.11% |
2007 Q2 | 115.34 Million USD | -3.2% |
2006 Q4 | 121.65 Million USD | 8.14% |
2006 Q1 | 148.33 Million USD | -0.34% |
2006 Q3 | 112.49 Million USD | -2.05% |
2006 Q2 | 114.84 Million USD | -22.58% |
2006 FY | 121.65 Million USD | -18.27% |
2005 Q4 | 148.84 Million USD | 2.86% |
2005 Q1 | 143.01 Million USD | -2.95% |
2005 FY | 148.84 Million USD | 1.01% |
2005 Q3 | 144.71 Million USD | -1.74% |
2005 Q2 | 147.27 Million USD | 2.98% |
2004 FY | 147.35 Million USD | 32.65% |
2004 Q1 | 107.47 Million USD | -3.25% |
2004 Q2 | 106.98 Million USD | -0.46% |
2004 Q3 | 112.44 Million USD | 5.1% |
2004 Q4 | 147.35 Million USD | 31.05% |
2003 Q3 | 79.51 Million USD | 4.33% |
2003 FY | 111.08 Million USD | 50.25% |
2003 Q2 | 76.21 Million USD | 3.33% |
2003 Q1 | 73.75 Million USD | -0.24% |
2003 Q4 | 111.08 Million USD | 39.71% |
2002 Q2 | 49.91 Million USD | 1.79% |
2002 FY | 73.93 Million USD | 51.06% |
2002 Q1 | 49.03 Million USD | 0.19% |
2002 Q3 | 49.84 Million USD | -0.14% |
2002 Q4 | 73.93 Million USD | 48.33% |
2001 Q1 | 12.14 Million USD | -18.78% |
2001 Q3 | 50.53 Million USD | 2.73% |
2001 Q4 | 48.94 Million USD | -3.15% |
2001 FY | 48.94 Million USD | 227.38% |
2001 Q2 | 49.19 Million USD | 305.13% |
2000 Q3 | 10.07 Million USD | -17.42% |
2000 Q4 | 14.95 Million USD | 48.42% |
2000 FY | 14.95 Million USD | 12.41% |
2000 Q1 | 12.77 Million USD | 0.0% |
2000 Q2 | 12.19 Million USD | -4.54% |
1999 FY | 13.3 Million USD | 0.0% |
1998 FY | - USD | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Editas Medicine, Inc. | 36.53 Million USD | -419.882% |
Dynavax Technologies Corporation | 256.91 Million USD | 26.067% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -357.399% |
Perrigo Company plc | 4.07 Billion USD | 95.337% |
Illumina, Inc. | 2.26 Billion USD | 91.603% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.456% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -18894.4% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 98.012% |
IQVIA Holdings Inc. | 14.23 Billion USD | 98.665% |
Heron Therapeutics, Inc. | 173.75 Million USD | -9.318% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 92.973% |
Unity Biotechnology, Inc. | 26.99 Million USD | -603.757% |
Waters Corporation | 2.35 Billion USD | 91.936% |
Biogen Inc. | 7.33 Billion USD | 97.412% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -398.488% |
Evolus, Inc. | 126.54 Million USD | -50.099% |
Adicet Bio, Inc. | 17.7 Million USD | -972.948% |
Cara Therapeutics, Inc. | 43.16 Million USD | -340.021% |
bluebird bio, Inc. | 330.32 Million USD | 42.498% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 64.887% |
FibroGen, Inc. | 170.45 Million USD | -11.434% |
Agilent Technologies, Inc. | 2.73 Billion USD | 93.055% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -809.509% |
Homology Medicines, Inc. | 44.05 Million USD | -331.162% |
Geron Corporation | 85.89 Million USD | -121.125% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 92.079% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 57.322% |
Myriad Genetics, Inc. | 145 Million USD | -30.996% |
Viking Therapeutics, Inc. | 1.26 Million USD | -14974.921% |
Intellia Therapeutics, Inc. | 115.34 Million USD | -64.673% |
Zoetis Inc. | 6.8 Billion USD | 97.208% |
Abeona Therapeutics Inc. | 4.4 Million USD | -4214.948% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 91.238% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 83.248% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 76.504% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -422.93% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 86.932% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -228.214% |
Verastem, Inc. | 41.55 Million USD | -357.069% |
Nektar Therapeutics | 230.4 Million USD | 17.559% |
Axsome Therapeutics, Inc. | 186.37 Million USD | -1.917% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -6079.05% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 86.402% |
OPKO Health, Inc. | 326.56 Million USD | 41.836% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 55.662% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -125690.728% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
uniQure N.V. | 138.4 Million USD | -37.234% |
Imunon, Inc. | 1.13 Million USD | -16572.094% |
Blueprint Medicines Corporation | 774.12 Million USD | 75.463% |
Insmed Incorporated | 1.2 Billion USD | 84.224% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 87.331% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -233.305% |
TG Therapeutics, Inc. | 110.79 Million USD | -71.437% |
Incyte Corporation | 38.28 Million USD | -396.106% |
Emergent BioSolutions Inc. | 877.5 Million USD | 78.354% |